Eplontersen

Phase 3

50%

Phase 3

Development Phase

1

Upcoming Catalysts

0

Historical Events

1

Regulatory Approvals

Upcoming Catalysts

Apr 2026~

IONS⭐Phase 3Phase 3

Eplontersen Phase 3 Results Expected

Eplontersen • Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

Drug Information

Target Indication

Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

Clinical Trial

Last updated: 12/4/2025

Regulatory Approvals

EMA3/5/2025

Wainzua

Treatment of hereditary transthyretin-mediated amyloidosis (ATTRv) in adult patients with stage 1 or stage 2 polyneuropathy.

Developer

IONS

Ionis Pharmaceuticals, Inc.